COVID-19 PANDEMİSİ SIRASINDA SKLERODERMALI HASTALARDA FONKSİYON, UYKU, YORGUNLUK VE YAŞAM KALİTESİ: KESİTSEL ÇALIŞMA

Öz

Amaç: İnsan sağlığını çeşitli şekillerde etkileyen COVID-19, Skleroderma hastalarının yaşamlarında da çeşitli etkilere ve kısıtlamalara neden olmuştur. Bu çalışmada Skleroderma hastalarında üst ekstremite fonksiyonları, uyku kalitesi, yorgunluk ve sağlıkla ilgili yaşam kalitesinin değerlendirilmesi ve üst ekstremite fonksiyonlarını etkileyen faktörlerin belirlenmesi amaçlandı. Yöntem: Çalışmaya toplam 83 katılımcı dahil edildi. Katılımcıların 39'u Skleroderma hastası (ortalama yaş 43,28±9,96 yıl) ve 44'ü sağlıklı kontrol (ortalama yaş 40,05±8,89 yıl) idi. Katılımcıların üst ekstremite fonksiyonlarını değerlendirmede Kol, Omuz ve El Sorunları Anketi ve Michigan El Sonuç Anketi uygulandı. Pittsburgh Uyku Kalitesi İndeksi, Yorgunluk Şiddet Ölçeği ve Skleroderma Sağlık Değerlendirme Anketi sırasıyla uyku kalitesini, yorgunluğu ve sağlıkla ilişkili yaşam kalitesini değerlendirmek için kullanıldı. Sonuçlar: Skleroderma hastaları, el fonksiyonları, uyku kalitesi, yorgunluk ve sağlıkla ilgili kalite açısından sağlıklı gruba göre anlamlı olarak daha düşük puanlara sahipti (p=0,001). Kol, Omuz ve El Sorunları Anketi puanı ile Pittsburgh Uyku Kalitesi İndeksi puanı (r=0,559, p=0,001), Yorgunluk Şiddet Ölçeği puanı (r=0,496, p=0,001), Skleroderma Sağlık Değerlendirme Anketi puanı (r=0,754, p=0,001) arasında pozitif yönde yüksek korelasyon vardı. Benzer şekilde Michigan El Sonuç Anketi puanı ile Skleroderma Sağlık Değerlendirme Anketi puanı arasında da yüksek korelasyon bulundu (r=-0,679, p=0,001). Tartışma: Sklerodermalı hastalarda üst ekstremite fonksiyonlarının ve sağlıkla ilgili yaşam kalitesinin etkilendiği bulundu. Üst ekstremite fonksiyonlarının uyku kalitesi, yorgunluk ve sağlıkla ilgili yaşam kalitesinden etkilendiği ortaya kondu. Dolayısıyla tüm bu etkileri ve birbirleriyle olan ilişkilerini bilmek Skleroderma hastalarında sistematik bir tedavi planı çizmeye olanak sağlar.

Anahtar Kelimeler

• Günlük Yaşam Aktiviteleri
• El
• Yaşam Kalitesi
• Sistemik Skleroz

FUNCTIONS, SLEEP, FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH SCLERODERMA DURING COVID-19: CROSS - SECTIONAL STUDY

Abstract

Purpose: COVID-19, which has affected people in various ways, has also shown to cause various limitations on the lives of Scleroderma patients. The current study aims at evaluating the upper extremity functions, sleep quality, fatigue, and health-related quality of life in Scleroderma patients and to determine the factors affecting upper extremity functions. Methods: A total of 83 participants were recruited in this study. Of the participants, 39 were Scleroderma patients (mean age 43.28±9.96 years) and 44 were healthy controls (mean age 40.05±8.89 years). The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH) and Michigan Hand Outcomes Questionnaire (MHQ) were applied to evaluate upper extremity functions of the participants. Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Scleroderma Health Assessment Questionnaire (SHAQ) were used to evaluate the sleep quality, fatigue, and health-related quality of life, respectively. Results: Scleroderma patients had significantly lower scores in hand functions, sleep quality, fatigue, and health-related quality than the healthy group (p=0.001). The correlations between DASH and PSQI (r=0.559, p=0.001), FSS (r=0.496, p=0.001), SHAQ scores (r=0.754, p=0.001) were highly positive. Similarly, a high correlation was found between MHQ and SHAQ scores (r=-0.679, p=0.001). Conclusion: Upper extremity functions and health-related quality of life were found to be affected in patients with Scleroderma. It was revealed that upper extremity functions were affected by sleep quality, fatigue, and health-related quality of life. Therefore, knowing all these effects and their relationships with each other allows to draw a systematic treatment plan on Scleroderma patients.

Keywords

• Activities of Daily Living
• Hand
• Quality of Life
• Systemic Sclerosis

Kaynakça

1. Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
3. He J, Si X, Ji M, Huang J, Zheng W, Wang J, et al. Effect of rhubarb on extravascular lung water in patients with acute respiratory distress syndrome. Rev Assoc Med Bras. 2017;63(5):435-440.
4. Pamuk ON, Balci MA, Donmez S, et al., editors. The incidence and prevalence of systemic sclerosis in northwestern part of Turkey. Arthritis Rheumatol. 2016;25(1):102-109.
5. Thombs BD, Jewett LR, Assassi S, Baron M, Bartlett SJ, Maia AC, et al. New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clin Exp Rheumatol. 2012;30(2071):23.
6. Ruaro B, Confalonieri M, Salton F, Wade B, Baratella E, Geri P, et al. The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. Pharmaceuticals (Basel). 2021;14(5):403.
7. van Laar JM, Stolk J, Tyndall A. Scleroderma Lung Pathogenesis, Evaluation and Current Therapy. Drugs 2007;67(7):985-996.
8. Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol. 2014;10(4):200-202.

9. Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier M-E, Hudson M, et al. The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. Clin Exp Rheumatol. 2018;113(4):88-94.
10. Nokes BT, Raza HA, Cartin-Ceba R, Lyng PJ, Krahn LE, Wesselius L, et al. Individuals with scleroderma may have increased risk of sleep-disordered breathing. J Clin Sleep Med. 2019;15(11):1665-1669.
11. Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology. 2018;57(2):370-381.
12. Denton CP, Campochiaro C, Bruni C, Distler O, Iagnocco A, Cerinic MM. COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. J Scleroderma Relat Disord. 2021; 6(1):58–65.
13. Karadag DT, Karakas F, Tekeoglu S, Yazici A, Isik OO, Cefle A. Validation of Turkish version of the Scleroderma Health Assessment Questionnaire. Clin Rheumatol. 2019;38(7):1917-1923.
14. Duger T, Yakut E, Oksüz C, Yorukan S, Bilgutay BS, Ayhan C, et al. Reliability and validity of the Turkish version of the Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire. Turk J Physiother Rehabil. 2006;17(3):99-107.
15. Schouffoer AA, van der Giesen FJ, Beaart-van de Voorde LJ, Wolterbeek R, Huizinga TW, Vliet Vlieland TP. Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis. Rheumatology. 2016;55(8):1386-1393.
16. Oksuz C, Akel BS, Oskay D, Leblebicioglu G, Hayran KM. Cross-cultural adaptation, validation, and reliability process of the Michigan Hand Outcomes Questionnaire in a Turkish population. J Hand Surg Am. 2011;36(3):486-492.
17. Agargun MY, Kara H, Anlar O. The validity and reliability of the Pittsburgh Sleep Quality Index. Turk Psikiyatri Derg. 1996;7(2):107-115.
18. Gencay-Can A, Can SS. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int. 2012;32(1):27-31.
19. Hoffmann-Vold AM, Distler O, Bruni C, Denton CP, Vries-Bouwstra J, Cerinic MM, et al. Systemic sclerosis in the time of COVID-19. Lancet Rheumatol. 2022;4(8):e566–e575.
20. Young A, Namas R, Dodge C, Khanna D. Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. Curr Treat Options in Rheum. 2016;2:252–269.
21. Yakut H, Özalevli S, Birlik AM. Fatigue and its relationship with disease-related factors in patients with systemic sclerosis: a cross-sectional study. Turk J Med Sci. 2021;51(2):530-539.
22. Liem S, Meessen J, Wolterbeek R, Marsan NA, Ninaber M, Vlieland TV, et al. Physical activity in patients with systemic sclerosis. Rheumatol Int. 2018;38(3):443-453.
23. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology. 2011;50(4):762-767.
24. Horsley-Silva JL, Umar SB, Vela MF, Griffing WL, Parish JM, DiBaise JK, et al. The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality. Diseases of the Esophagus. 2019;32(5):1–6.
25. Odonwodo A, Badri T, Hariz A. Scleroderma (Systemic Sclerosis). StatPearls Treasure Island (FL): StatPearls Publishing. 2020.
26. Kallen MA, Mayes MD, Kriseman YL, De Achaval SB, Cox VL, Suarez-Almazor ME. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol. 2010;37(8):1692-1698.